SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025. Red Cat, together with its subsidiaries, provides various products, services, and solutions to the U.S. drone industry. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins ...

SAN FRANCISCO, June 3, 2025 /PRNewswire/ -- On June 2, 2025, Airbnb (NASDAQ: ABNB) learned that the company and certain of its directors and executives were named as defendants in a lawsuit filed in the U.S. District Court for the District of Delaware by The Heritage Foundation and American Conservative Values ETF.The complaint alleges, among other things, that Airbnb improperly excluded certain shareholder proposals from its 2025 definitive proxy statement on Schedule 14A filed with the U.S. Securities and ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by directors and officers of Quantum Computing Inc. (QCI), focusing on their obligations to shareholders [1]. Group 1: Legal Investigation - A class action complaint has been filed against QCI, alleging that the defendants made false and misleading statements regarding the company's quantum computing technologies and relationships with NASA [3]. - The complaint claims that QCI overstated its technological capabilities, the nature of its contracts with NASA, and its progress in developing a TFLN foundry [3]. - It is alleged that QCI's revenues were partially based on undisclosed related party transactions, which could significantly harm the company's business and reputation once revealed [3]. Group 2: Shareholder Rights - Current long-term QCI shareholders may have legal claims that can be brought against the company's directors and officers [2]. - Shareholders interested in discussing their legal rights are encouraged to contact the lead analyst at Johnson Fistel [2].

Group 1: Company Performance - Carlisle Companies Incorporated (CSL) is benefiting from strong performance in the Carlisle Construction Materials (CCM) segment, with a 2% year-over-year revenue increase in Q1 2025 driven by robust demand for reroofing products and healthy construction activity [1] - The acquisition of MTL Holdings positively impacted sales by 4.6% in Q1 2025, enhancing CSL's architectural metals business and broadening customer offerings [3] - CSL's dividend payments in Q1 2025 totaled $45.2 million, an increase of 8.9% year-over-year, while share buybacks reached $400 million, up 166.5% year-over-year [4] Group 2: Acquisitions and Market Expansion - CSL has strengthened its business through strategic acquisitions, including ThermaFoam in February 2025, which enhanced its Insulfoam EPS business and expanded its presence in Texas and the South-Central U.S. market [2] - The acquisition of Plasti-Fab in December 2024 expanded CSL's building envelope product portfolio, reinforcing its position in the North American polystyrene insulation market [2] Group 3: Segment Challenges - The Carlisle Weatherproofing Technologies (CWT) segment experienced an 11.7% decline in organic revenues in Q1 2025 due to a slowdown in the residential construction market and project delays [9] - High selling, general, and administrative expenses have adversely impacted CSL, with a 1.8% increase in cost of sales and a 16.3% rise in selling and administrative expenses year-over-year in Q1 2025 [10]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY). On June 2, 2025, Blueprint Medicines announced the execution of a definitive agreement with Sanofi for the acquisition of all outstanding shares of Blueprint Medicines for $129.00 per share in cash. Whereas shareholders also ...

Key Takeaways CM's Q2 adjusted EPS rose 17% to C$2.05, driven by higher revenues and loan and deposit growth. Total revenues climbed 14% to C$7.02B, led by gains in both net interest and non-interest income. Provision for credit losses jumped 18% to C$605M, while expenses rose 9% to C$3.82B.Canadian Imperial Bank of Commerce (CM) announced second-quarter fiscal 2025 (ended April 30) results last week. Adjusted earnings per share of C$2.05 increased 17% from the prior-year quarter.Results benefited from gr ...

Core Viewpoint - Theravance Biopharma has entered into a definitive agreement to sell its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash, translating confidence in Trelegy's sustained success into immediate value for shareholders [1][2] Financial Summary - The sale of Outer Year Royalties will provide Theravance Biopharma with $225 million in cash, in addition to the $1.1 billion received from the initial sale of Trelegy royalty interests in 2022, bringing the total potential lifetime value from Trelegy monetization efforts to $1.525 billion [3][6] - The company retains rights to receive up to $150 million in remaining Trelegy sales-related milestones in 2025 and 2026 from Royalty Pharma, with minimal growth required over 2024 actuals to achieve these milestones [3][6] Strategic Review Committee - This transaction is the first outcome of the ongoing efforts of the Strategic Review Committee formed by the Board of Directors to assess strategic alternatives and enhance shareholder value [4] - The Committee will continue to evaluate various alternatives to maximize shareholder value, although there is no assurance that additional transactions will occur [4] Product Development - Theravance Biopharma is focused on growing YUPELRI and advancing ampreloxetine towards potential regulatory approval and launch, indicating a commitment to developing its product pipeline [2][8]

Core Viewpoint - The DoubleVerify Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misleading statements and undisclosed risks impacting the company's stock performance during the specified class period [1][3]. Company Allegations - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, affecting its competitive position [3]. - It is alleged that the development of technology for closed platforms was more expensive and time-consuming than disclosed, limiting DoubleVerify's ability to monetize its Activation Services [3]. - Competitors were reportedly better positioned to incorporate AI into their offerings, which negatively impacted DoubleVerify's profits and competitive edge [3]. - The company is accused of systematically overbilling customers for ad impressions served to bots, and its risk disclosures were misleading, presenting adverse facts as mere possibilities [3]. Stock Performance Impact - Following a lower revenue growth expectation announcement on February 28, 2024, DoubleVerify's stock price fell over 21% [4]. - On May 7, 2024, after cutting its full-year 2024 revenue outlook due to reduced customer ad spending, the stock price dropped nearly 39% [5]. - A report on February 27, 2025, detailing lower-than-expected sales and earnings due to reduced customer spending led to a further stock price decline of more than 36% [6]. Legal Process - Investors who purchased DoubleVerify common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - The lawsuit also states that Organon intended to prioritize debt reduction following its acquisition of Dermavant Sciences Ltd [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results, announcing a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].